SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
SOHM (OTC:SHMN) has achieved a significant breakthrough in gene editing technology with its proprietary ABBIE platform version 2. The company successfully demonstrated that its advanced dCas12a domain can effectively modify human cells, enabling multi-target editing capabilities through crRNA arrays.
The company has also successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression, demonstrating immediate commercial applications in drug screening, research partnerships, and diagnostic development. This positions SOHM for strategic partnerships and licensing opportunities in the rapidly growing genome editing market, projected to reach $25 billion by 2030 with a CAGR of 16.1%.
SOHM (OTC:SHMN) ha raggiunto una svolta importante nella tecnologia di editing genico con la sua piattaforma proprietaria ABBIE versione 2. L'azienda ha dimostrato con successo che il suo avanzato dominio dCas12a può modificare efficacemente cellule umane, permettendo modifiche multiple bersaglio tramite array di crRNA.
Inoltre ha clonato con successo una linea cellulare di carcinoma ovarico con sovraespressione confermata dell'enzima GYS1, evidenziando immediati sbocchi commerciali in screening farmacologici, collaborazioni di ricerca e sviluppo diagnostico. Ciò posiziona SOHM per partnership strategiche e opportunità di licenza in un mercato dell'editing genomico in rapida crescita, stimato raggiungere $25 billion by 2030 con un CAGR del 16,1%.
SOHM (OTC:SHMN) ha logrado un avance importante en la tecnología de edición genética con su plataforma propietaria ABBIE versión 2. La compañía demostró con éxito que su avanzado dominio dCas12a puede modificar células humanas de forma efectiva, permitiendo edición multi-objetivo mediante arreglos de crRNA.
También ha clonado con éxito una línea celular de cáncer de ovario con sobreexpresión confirmada de la enzima GYS1, mostrando aplicaciones comerciales inmediatas en cribado de fármacos, colaboraciones de investigación y desarrollo de diagnósticos. Esto posiciona a SOHM para asociaciones estratégicas y oportunidades de licencia en el mercado de edición genómica, que se espera alcance $25 billion by 2030 con una tasa compuesta anual del 16,1%.
SOHM (OTC:SHMN)는 자체 개발한 ABBIE 플랫폼 버전 2로 유전자 편집 기술에 있어 중요한 돌파구를 이뤘습니다. 회사는 진보된 dCas12a 도메인이 인체 세포를 효과적으로 변형할 수 있음을 입증했으며, crRNA 배열을 통해 다중 표적 편집이 가능함을 확인했습니다.
또한 GYS1 효소가 과발현된 것을 확인한 난소암 세포주를 성공적으로 클론화하여 약물 스크리닝, 연구 파트너십, 진단 개발 등 즉각적인 상업적 활용 가능성을 보여주었습니다. 이는 SOHM을 전략적 파트너십 및 라이선스 기회의 유리한 위치에 두며, 유전체 편집 시장은 연평균 성장률 16.1%로 2030년까지 $25 billion by 2030 규모에 이를 것으로 전망됩니다.
SOHM (OTC:SHMN) a réalisé une avancée importante dans la technologie d'édition génomique avec sa plateforme propriétaire ABBIE version 2. L'entreprise a démontré avec succès que son domaine dCas12a avancé peut modifier efficacement des cellules humaines, permettant des éditions multi-cibles via des matrices de crRNA.
Elle a également cloné avec succès une lignée cellulaire de cancer de l'ovaire présentant une surexpression confirmée de l'enzyme GYS1, montrant des applications commerciales immédiates en criblage de médicaments, partenariats de recherche et développement de diagnostics. Cela positionne SOHM pour des partenariats stratégiques et des opportunités de licence sur le marché de l'édition génomique en forte croissance, estimé atteindre $25 billion by 2030 avec un TCAC de 16,1%.
SOHM (OTC:SHMN) hat mit seiner firmeneigenen ABBIE Plattform Version 2 einen bedeutenden Durchbruch in der Geneditierungstechnologie erzielt. Das Unternehmen hat erfolgreich nachgewiesen, dass seine fortschrittliche dCas12a-Domäne menschliche Zellen effektiv modifizieren kann und Mehrfachzielbearbeitungen mittels crRNA-Arrays ermöglicht.
Ferner clonierte das Unternehmen erfolgreich eine Ovarialkarzinom-Zelllinie mit nachgewiesener Überexpression des Enzyms GYS1, was unmittelbare kommerzielle Anwendungen in der Wirkstoffscreening, Forschungskooperationen und Diagnostikentwicklung demonstriert. Damit positioniert sich SOHM für strategische Partnerschaften und Lizenzierungschancen in dem schnell wachsenden Geneditierungsmarkt, der voraussichtlich bis 2030 $25 billion by 2030 erreichen wird bei einer CAGR von 16,1%.
- Successfully demonstrated advanced dCas12a domain technology for human cell modification
- Achieved multi-target editing capabilities through crRNA arrays
- Successfully cloned ovarian cancer cell line with GYS1 enzyme overexpression
- Positioned to capture share of growing genome editing market projected to reach $25B by 2030
- Enhanced potential for strategic partnerships and licensing opportunities
- Early-stage development company with inherent uncertainties
- Operating in highly competitive gene editing market
- No immediate revenue generation from technology platform
Advanced dCas12a Technology Successfully Modifies Human Cells, Positioning Company for Multi-Target Editing Capabilities
CHINO HILLS, CALIFORNIA / ACCESS Newswire / August 26, 2025 / SOHM, Inc. (OTC PINK:SHMN), - SOHM, a leading pharmaceutical company developing next-generation gene editing solutions, today announced a significant milestone in the development of its proprietary ABBIE platform. The company has successfully demonstrated that ABBIE version 2, featuring an advanced dCas12a domain, can effectively modify cultured human cells, marking a critical advancement toward commercial-ready gene editing technology.
Breakthrough Technology Platform
This latest achievement represents a substantial upgrade from previous iterations, with the new dCas12a domain replacing the earlier dCas9 technology to deliver enhanced functionality and precision. The breakthrough positions SOHM to pursue simultaneous multi-target editing capabilities through crRNA arrays, potentially offering unprecedented efficiency in gene modification applications.
"This milestone validates our scientific approach and brings us significantly closer to realizing the full potential of our ABBIE platform," said Dr. David Aguilar, COO.
Proven Applications in Drug Discovery
Complementing the core platform advancement, SOHM has successfully cloned an ovarian cancer cell line with confirmed GYS1 enzyme overexpression. These specialized cellular tools demonstrate immediate commercial applications including:
Drug screening capabilities for targeted therapeutics such as GYS1 inhibitors
Research applications for academic and pharmaceutical partnerships
Diagnostic development opportunities across multiple therapeutic areas
Strategic Partnership and Licensing Implications
The technological advancements significantly enhance and improve SOHM's position for strategic partnerships and out licensing opportunities. The proven ability to create specialized cellular tools and modify human cells positions the company to engage with pharmaceutical partners, research institutions, and biotechnology companies seeking advanced gene editing solutions.
The company's out licensing strategy will focus on leveraging the ABBIE platform's multi-target capabilities and proven cellular engineering applications to create value across multiple therapeutic areas and research applications.
Revenue Implications:
Global Gene Editing Market: The global genome editing market size was estimated at USD 9.78 billion in 2024 and is projected to reach USD 25.00 billion by 2030, growing at a CAGR of
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted solutions for gene editing. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original press release on ACCESS Newswire
FAQ
What breakthrough did SOHM (SHMN) announce in gene editing technology?
How large is the genome editing market potential for SOHM (SHMN)?
What immediate commercial applications does SOHM's technology offer?
How does SOHM's new dCas12a technology differ from previous versions?
What strategic opportunities does this breakthrough create for SOHM?
